Changes in Glucose-lipid Metabolism, Insulin Resistance, and Inflammatory Factors in Patients with Autoimmune Thyroid Disease
Overview
Biotechnology
Pathology
Authors
Affiliations
Background: Autoimmune thyroid disease (AITD) is a common organ-specific autoimmune disorder, and genetic, environmental, and endogenous factors are responsible for initiation of thyroid autoimmunity. Some AITD patients suffer from a certain degree of glucose-lipid metabolism disorder. This study aims to explore the changes in glucose-lipid metabolism, insulin resistance, and inflammatory factors in patients with AITD.
Methods: A total of 91 patients with Hashimoto's thyroiditis were retrospectively analyzed and divided into hypothyroidism group (n = 42) and normal thyroid group (n = 49), while 50 healthy people were selected as control group. The changes in glucose-lipid metabolism, insulin resistance, and inflammatory factors in each group were compared, and their correlations with the thyroid function were analyzed.
Results: The levels of serum interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), IL-12, IL-10, (FINS), and homeostasis model assessment of insulin resistance (HOMA-IR) were gradually declined in sequence of hypothyroidism group, normal thyroid group, and control group (P < 0.05). In hypothyroidism group, the levels of serum-free triiodothyronine (FT3), free thyroxine (FT4), (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) were significantly lower than those in normal thyroid group (P < 0.05), while the level of serum thyroid stimulating hormone (TSH) was significantly higher than that in normal thyroid group (P < 0.05). However, the fasting blood glucose and 2-hour postprandial blood glucose levels had no statistically significant differences among the three groups (P > 0.05).
Conclusion: Autoimmune thyroid disease patients are prone to fat metabolism disorder, and the serum thyroid hormone level has a close correlation with blood lipid metabolism, insulin metabolism, and inflammatory factors.
Prasai M, Lomre M, Jelloul E, Kleynen P, Veltri F, Sitoris G Eur Thyroid J. 2025; 14(1).
PMID: 39888679 PMC: 11850046. DOI: 10.1530/ETJ-24-0339.
Couto B, Neves C, Neves J, Delgado L BMC Endocr Disord. 2024; 24(1):281.
PMID: 39741265 PMC: 11687027. DOI: 10.1186/s12902-024-01765-4.
Zhou J, Cao C, Liu T, Wu L, Miao J Diabetes Metab Syndr Obes. 2024; 17:4267-4275.
PMID: 39564449 PMC: 11575458. DOI: 10.2147/DMSO.S481433.
Risk factors of thyroid dysfunction in patients with rheumatoid arthritis.
Li L, Jiao F, Zhao J, Duan L Cent Eur J Immunol. 2024; 49(2):126-131.
PMID: 39381558 PMC: 11457566. DOI: 10.5114/ceji.2024.140634.
Chen Y, Jiang B, Qu C, Jiang C, Zhang C, Wang Y Front Endocrinol (Lausanne). 2024; 15:1424957.
PMID: 39045270 PMC: 11263034. DOI: 10.3389/fendo.2024.1424957.